Stemline Therapeutics Inc (STML) COO Sells $368,408.59 in Stock

Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman sold 25,817 shares of Stemline Therapeutics stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $14.27, for a total transaction of $368,408.59. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Kenneth Hoberman also recently made the following trade(s):

  • On Monday, March 11th, Kenneth Hoberman sold 25,101 shares of Stemline Therapeutics stock. The stock was sold at an average price of $11.11, for a total transaction of $278,872.11.
  • On Thursday, March 7th, Kenneth Hoberman sold 2,995 shares of Stemline Therapeutics stock. The stock was sold at an average price of $11.36, for a total transaction of $34,023.20.
  • On Monday, February 25th, Kenneth Hoberman sold 10,557 shares of Stemline Therapeutics stock. The shares were sold at an average price of $12.05, for a total transaction of $127,211.85.

STML traded down $0.07 during trading on Friday, hitting $14.55. The company had a trading volume of 347,717 shares, compared to its average volume of 679,300. The stock has a market capitalization of $635.62 million, a P/E ratio of -4.87 and a beta of 1.20. Stemline Therapeutics Inc has a one year low of $7.82 and a one year high of $20.55. The company has a current ratio of 5.07, a quick ratio of 2.97 and a debt-to-equity ratio of 0.01.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.06). The business had revenue of $5.05 million for the quarter, compared to analysts’ expectations of $2.61 million. On average, equities research analysts predict that Stemline Therapeutics Inc will post -2.08 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of the business. Legal & General Group Plc increased its stake in Stemline Therapeutics by 27.1% in the 4th quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 1,120 shares during the last quarter. Knott David M increased its stake in Stemline Therapeutics by 1.3% in the 1st quarter. Knott David M now owns 157,795 shares of the biopharmaceutical company’s stock valued at $2,028,000 after buying an additional 2,000 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Stemline Therapeutics in the 1st quarter valued at $36,000. Virtus ETF Advisers LLC increased its stake in Stemline Therapeutics by 11.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 29,723 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 2,982 shares during the last quarter. Finally, Voya Investment Management LLC increased its stake in Stemline Therapeutics by 31.2% in the 1st quarter. Voya Investment Management LLC now owns 14,522 shares of the biopharmaceutical company’s stock valued at $187,000 after buying an additional 3,453 shares during the last quarter. Hedge funds and other institutional investors own 48.38% of the company’s stock.

Several research firms recently commented on STML. Piper Jaffray Companies set a $23.00 price objective on shares of Stemline Therapeutics and gave the company a “buy” rating in a research report on Monday, March 18th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Stemline Therapeutics in a research report on Friday, January 25th. ValuEngine raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. BidaskClub cut shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Wedbush cut shares of Stemline Therapeutics from an “outperform” rating to a “neutral” rating and set a $18.00 price objective on the stock. in a research report on Monday. They noted that the move was a valuation call. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Stemline Therapeutics presently has an average rating of “Buy” and an average target price of $25.20.

COPYRIGHT VIOLATION NOTICE: “Stemline Therapeutics Inc (STML) COO Sells $368,408.59 in Stock” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2019/05/17/stemline-therapeutics-inc-stml-coo-sells-368408-59-in-stock.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Read More: What is Forex?

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply